SUMMARY Oral timolol, a beta-adrenergic receptor blocker, was given in 5 different doses from 5 mg to 30 mg a day to 12 healthy volunteers in a double-blind cross-over trial. Adrenaline was instilled into one eye in each subject. Recordings of intraocular pressure during the trial suggested the presence of a dose-response relationship between the dose of timolol and the decrease of intraocular pressure. An analysis of the interaction of timolol and adrenaline showed that the adrenaline effect diminished linearly with increasing timolol dose, which finally made the combination less effective than timolol alone.
Most of the reports concerning the reduction of intraocular pressure by timolol maleate deal with topical timolol in clinical studies. To the best of our knowledge only one study reports on the reduction of intraocular pressure by oral timolol, and in that study' only a single dose of 5 mg oral timolol was used. Thus the effects on intraocular pressure of systemically adm--inistered timolol have not been fully investigated.
Earlier investigations have given contradictory results, suggesting both additive and antagonistic effects of combining timolol and adrenaline.2" As this combination avoids the disadvantages of miotics it could be a useful tool in the treatment of glaucoma. Earlier reports with oral beta-receptor blockers in the treatment of glaucoma57 have encouraged the use of this alternative oral treatment when carbonic anhydrase inhibitors are unsuitable.
However, there has been no dose-response study on the subject of systemically administered timolol. This study was designed to investigate the effect on intraocular pressure of different doses of oral timolol and also the effect of simultaneously administered adrenaline.
Material and methods
The study was approved by the Ethical Committee of the Central Hospital Vasteras, and followed the guidelines of the Tokyo-Helsinki convention. The trial-was of randomised, double-blind, cross-over Correspondence to Dr A. Ohrstr6m , Department of Ophthalmology Hospital of Koping. S-731 00 K6ping, Sweden. design (Fig. 1) . Twelve volunteers, all females, age range 18 to 50 years, participated in the study. Timolol maleate tablets in 5 different strengths (2 5, 5, 7 5, 10, and 15 mg) were dispensed by the local pharmacy. Lactose was used in the placebo tablets. Adrenaline borate 1% eye drops (Eppy) and 0 9% saline as placebo drops were used to investigate the effect of adrenaline. One drop of placebo was instilled into one eye and one drop of adrenaline into the other, the distribution being randomised but balanced, so that 6 of the subjects received adrenaline in the right eye and the other 6 in the left. IOP 'OP 10.00 a. 
Results
During the third week one of the subjects developed bradycardia (45 beats/min) and had to leave the study. Her dose of timolol was 10 mg a day. The other 11 subjects completed the trial without any complications. The statistical analysis was based on a total of 1320 recordings of intraocular pressure (TOP).
Oral timolol used alone decreased the intraocular pressure significantly, p<0-001 (Table 1 and Fig. 2 ). In the full analysis of variance including both eyes treated with placebo drops and adrenaline the contrasts between eyes (reaction of IOP) and between timolol doses were not statistically significant, showing no further lowering of the IOP with increasing timolol doses.
However, when the half of the material (Table 2) in which no adrenaline was applied was analysed (Table   3 ), an increase in timolol dose was followed by a decrease in IOP values (p<005), which suggests a tendency towards a dose-response relationship.
An individual analysis of IOP responses revealed that one of the subjects reacted with an increase of IOP after adrenaline. This increase was significant both with placebo tablets (p<0-0l) and with different doses of timolol (p<0-00l). This remarkable response prompted us to check this particular subject's reaction in a trial3 of oral timolol and adrenaline performed one year previously. An analysis of variance showed (p<0-01) a significant inverse reaction to adrenaline in that trial also. An analysis of the pure effect of adrenaline (placebo/placebo versus placebo/adrenaline) in the present trial would have shown, if the values of this particular subject had been excluded, that it usually caused a highly significant decrease of IOP (p<0-001). However, in order not to disturb the validity of the statistical analysis no values were excluded, and the tables thus include this inverse reaction.
When differences in IOP values were found between adrenaline-and placebo-treated eyes at the 5 dose levels of timolol, a linear correlation of the means emerged (Table 1, Fig. 3 ), which is suggestive of a gradual inhibition of the adrenaline effect with increasing timolol dose. An analysis of this correlation using the mean IOP differences gave p<0001 by parametric methods and p<00083 by the nonparametric Kendall rank correlation test.
The statistical analysis showed no significant changes between the differences of tension in the eyes on different days. A slight heterogeneity was shown in the analysis of the importance of time of measurement and of the response of individual subjects, but no tendency could be shown. This study shows that oral timolol lowers intraocular pressure when compared with placebo. A dose-response relationship seems to exist, but after 5 mg the further decrements of pressure with increasing dose are very small. A similar result was found in another study on timolol,3 when 2 doses (5 mg and 20 mg) were used.
The interaction of beta blockers and adrenaline is controversial. Favourable results with topical timolol and adrenaline showing an additive IOP-reducing effect have been reported. 4 12-15 With the combination of topical atenolol and adrenaline Rushton'6 reported an additive hypotensive effect. Higgins and Brubaker ' found that adrenaline and topical timolol had an additive effect on inhibiting the formation of aqueous humour, but found no significant change in the IOP.
On the other hand Phillips et al. 8 reported that the combination of local atenolol and adrenaline was less effective than atenolol alone, and Boger et al. ' The present study (Fig. 3) shows that the effect of adrenaline diminishes linearly as the timolol dose is increased and that this finally makes the combination less effective than timolol alone.
As beta blockers act by competitive inhibition, a high oral timolol dose should provide a greater degree of beta blockade than a low dose. The doses used in this trial (5 mg-30 mg a day) could be expected to produce a beta receptor blockade ranging from weak to strong. The dose-response curve (Fig. 2) The reduction of IOP by topical timolol has been shown by fluorophotometry to be due to a decreased formation of aqueous humour.24 In a fluorophotometric study Townsend and Brubaker25 showed that the immediate effect of adrenaline is to raise the facility of outflow and to increase the production of aqueous humour. A comparison between timolol and adrenaline shows that the IOP-reducing effect of topical timolol is significantly greater than that of adrenaline 26 There is no reason to believe that the basic mechanism producing the reduction of IOP differs between oral or topical timolol. Earlier observations of additive effects with low timolol doses and antagonistic effects with high timolol doses,3 and the finding of this trial that increasing the timolol dose decreases the effect of adrenaline, can be explained if a low dose of timolol combined with adrenaline decreases aqueous humour production and increases the facility of outflow, while a high dose of timolol still produces a decrease of aqueous humour but blocks the adrenaline-mediated increase of facility. A similar theory is proposed by Thomas and Epstein'5 based on a study of the interaction of topical timolol and adrenaline showing a transient additive effect. The simultaneous stimulation by adrenaline of aqueous humour production would explain why a high dose of timolol combined with adrenaline is less effective than timolol used alone.
Since the beginning of the last decade oral beta receptor blockers, usually propranolol, have been used in the treatment of glaucoma.562728 This use of oral beta blockers is controversial and beyond the scope of the present discussion. However, when a patient with arterial hypertension and glaucoma needs treatment for both diseases, an oral beta blocker seems to be the drug of choice. The results of this study on healthy volunteers suggest that there are no benefits in using high doses of oral beta receptor blockers in the treatment of glaucoma.
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